Trimethylamine N-Oxide Promotes Vascular Inflammation Through Signaling of Mitogen-Activated Protein Kinase and Nuclear Factor-κB

Marcus M. Seldin, PhD; Yonghong Meng, MD; Hongxiu Qi, BS; WeiFei Zhu, PhD; Zeneng Wang, PhD; Stanley L. Hazen, MD, PhD; Aldons J. Lusis, PhD; Diana M. Shih, PhD

Background—The choline-derived metabolite trimethylamine N-oxide (TMAO) has been demonstrated to contribute to atherosclerosis and is associated with coronary artery disease risk.

Methods and Results—We explored the impact of TMAO on endothelial and smooth muscle cell function in vivo, focusing on disease-relevant outcomes for atherogenesis. Initially, we observed that aortas of LDLR−/− mice fed a choline diet showed elevated inflammatory gene expression compared with controls. Acute TMAO injection at physiological levels was sufficient to induce the same inflammatory markers and activate the well-known mitogen-activated protein kinase, extracellular signal–related kinase, and nuclear factor-κB signaling cascade. These observations were recapitulated in primary human aortic endothelial cells and vascular smooth muscle cells. We also found that TMAO promotes recruitment of activated leukocytes to endothelial cells. Through pharmacological inhibition, we further showed that activation of nuclear factor-κB signaling was necessary for TMAO to induce inflammatory gene expression in both of these relevant cell types as well as endothelial cell adhesion of leukocytes.

Conclusions—Our results suggest a likely contributory mechanism for TMAO-dependent enhancement in atherosclerosis and cardiovascular risks. (J Am Heart Assoc. 2016;5:e002767 doi: 10.1161/JAHA.115.002767)

Key Words: atherosclerosis • cardiovascular disease • endothelial cell • inflammation • leukocyte adhesion • nuclear factor-κB signaling • trimethylamine N-oxide • vascular smooth muscle cell

Numerous recent case–control and longitudinal studies have shown a striking association between trimethylamine N-oxide (TMAO) levels and cardiovascular disease risks in a variety of cohorts.1–10 TMAO is derived primarily from dietary choline and carnitine through the action of gut microbiota, which metabolize these constituents to trimethylamine (TMA).1,11,12 TMA is absorbed in turn and travels via the portal circulation to the liver, where it is oxidized by flavin-containing monooxygenases, primarily FMO3, to TMAO.1,11,12 In studies in mice, supplementation with dietary choline, carnitine, precarnitine (γ-butyrobetaine), or even TMAO alone was sufficient to enhance macrophage cholesterol accumulation and atherogenic plaque formation, supporting a causal relationship.1,2,11 TMAO also has significant effects on cholesterol metabolism in the bile acid compartments.1,11

We report studies of the effects of elevated TMAO levels on vascular cells in vitro and in vivo. The development of atherosclerosis is preceded by functional and transcriptional changes in vascular endothelial and smooth muscle cells and by the accumulation of subendothelial low-density lipoprotein particles.13,14 We provide evidence that TMAO directly activates inflammatory pathways, including nuclear factor-κB (NF-κB) signaling in both human aortic endothelial cells (HAECs) and smooth muscle cells, providing another potential pathway by which TMAO contributes to coronary artery disease.

Methods

Animals

All animal experiments were approved by the University of California Los Angeles animal care and use committee, in accordance with public health service guidelines. For choline feeding studies, female LDLR knockout (LDLR−/−) mice aged 8 weeks and on a C57BL/6J background were purchased from the Jackson Laboratory (Bar Harbor, ME). Beginning at 9 weeks of age, the mice were given acidified water...
supplemented with or without 1.3% choline chloride (n=8 for each group) for 3 weeks. At the end of the treatment period, the mice were fasted for 4 hours before blood and tissues were collected for further analysis. For acute TMAO exposure studies, LDLR−/− female mice were fasted for 4 hours and then injected with vehicle or TMAO (86 μmol; n=3 for each group) for various periods of time before aorta samples were collected for examination of activation of signaling pathways or inflammatory gene expression.

**Cell Culture**

HAECs were cultured, as described previously. In brief, HAECs were isolated from anonymous discarded aorta clippings from heart transplant donors and expanded into primary cultures. The culture dishes or plates for HAECs were coated with 0.1% gelatin solution. HAECs were cultured in M199 medium supplemented with 20% FBS (Atlanta Biologicals), 100 U/mL penicillin, 100 μg/mL streptomycin, 1 mmol/L sodium pyruvate, 65 μg/mL heparin (Sigma-Aldrich), and 50 μg/mL endothelial cell growth supplement (BD Biosciences). Leukocytes for adhesion assay were grown in RPMI media with 2% heat-inactivated FBS (Atlanta Biologicals), 100 U/mL penicillin, and 100 μg/mL streptomycin. Primary human vascular smooth muscle cells (VSMCs) were cultured in 0.1% gelatin solution using DMEM supplemented with 20% FBS (Atlanta Biologicals), 100 U/mL penicillin, 100 μg/mL streptomycin, and 1 mmol/L sodium pyruvate. Cell culture treatments were carried out in DMEM supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, 1 mmol/L sodium pyruvate, and 5% FBS for the indicated period of time. Treatments using TMA in media were prepared from a salt form of the compound TMA-HCl, which was purchased from Sigma-Aldrich. For signaling experiments, cells were placed in DMEM containing 5% FBS and penicillin/streptomycin for 2 hours to acclimate the cells and reduce background prior to the addition of treatments. All experiments using primary human cells were repeated in at least 3 separate donors to confirm robust function of TMAO.

**RNA Extraction and Reverse Transcription**

Cells or tissue were homogenized in QIAzol (Qiagen), and RNA extraction was carried out using the manufacturer’s protocol. RNA samples were reverse transcribed using a high-capacity cDNA reverse transcription kit (Applied Biosystems) with random primers.

**Quantitative Polymerase Chain Reaction**

Quantitative polymerase chain reaction (qPCR) was carried out using a KAPA SYBR Fast qPCR kit (Kapa Biosystems), as recommended by the manufacturer. Samples were run on a LightCycler 480 II (Roche) and analyzed using the Roche LightCycler 1.5.0 software. All qPCR targets were normalized to RPL13A expression and quantified using the ΔΔCt method. All qPCR primer sequences were obtained from PrimerBank and are listed in Table.

<table>
<thead>
<tr>
<th>Primer Name</th>
<th>Target Species</th>
<th>Fwd Sequence 5′→3′</th>
<th>Rev Sequence 5′→3′</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD68</td>
<td>Mouse</td>
<td>gacctacatcagagccgagt</td>
<td>cggcatgaatgctcagt</td>
</tr>
<tr>
<td>COX-2</td>
<td>Mouse</td>
<td>TTCAACACACTTACTCAGGTC</td>
<td>AGAAGGGTTCGGAGTACCAT</td>
</tr>
<tr>
<td>E-Selectin</td>
<td>Mouse</td>
<td>ATGGCTGGGCTTTTCTCTC</td>
<td>GTAGTCCGGCTGACAGATGC</td>
</tr>
<tr>
<td>iCAM1</td>
<td>Mouse</td>
<td>cccacgctacctctgc</td>
<td>gatggatacttgacatcc</td>
</tr>
<tr>
<td>KC</td>
<td>Mouse</td>
<td>CTCAAGAATGTCGCGAGGCT</td>
<td>AGAGCAGTCTGTCCTTCTCGTT</td>
</tr>
<tr>
<td>MCP-1</td>
<td>Mouse</td>
<td>CTCTTGGGGCTCTGTCCA</td>
<td>CAGGCTACTCATGGGATCA</td>
</tr>
<tr>
<td>MIP-2</td>
<td>Mouse</td>
<td>GGTTCTTCTGGTGAGGACA</td>
<td>TCCAGAGCTTAGTGAGC</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Mouse</td>
<td>cgttagaccaagcttgatagc</td>
<td>ttgatgtcatcgccttg</td>
</tr>
<tr>
<td>VCAM1</td>
<td>Mouse</td>
<td>CTGTTCAAGCGAGGTCTCAC</td>
<td>CAGGCAATAGCGACAC</td>
</tr>
<tr>
<td>IL-1b</td>
<td>Mouse</td>
<td>aggtagcaggaacccaaag</td>
<td>agcgtgtatgtcatcag</td>
</tr>
<tr>
<td>IL-6</td>
<td>Mouse</td>
<td>gctcaaaaaactgtgataatacga</td>
<td>ccagctagctatctgtctac</td>
</tr>
<tr>
<td>COX-2</td>
<td>Human</td>
<td>cttacgcatacttttcaag</td>
<td>tcaccgtaaatatgatlaag</td>
</tr>
<tr>
<td>E-Selectin</td>
<td>Human</td>
<td>cccgaaggggtttggaag</td>
<td>cggagaactccgaggct</td>
</tr>
<tr>
<td>iCAM1</td>
<td>Human</td>
<td>tctgtcgccccgaagact</td>
<td>ggaggtcgtgctgtg</td>
</tr>
<tr>
<td>IL-6</td>
<td>Human</td>
<td>TTCAATGAGGAGACTTGGCTG</td>
<td>CGGACTTTGCGGAGGTC</td>
</tr>
</tbody>
</table>

COX-2 indicates cyclooxygenase 2; IL, interleukin; MCP-1, monocyte chemotactic protein 1; MIP-2, macrophage inflammatory protein 2; TNF-α, tumor necrosis factor-α.
Nuclear and Cytosolic Fractionation

Cell lysates were fractionated using NE-PER kits (Thermo Scientific). Approximately $5 \times 10^6$ cells per condition were pelleted via centrifugation and then fractionated by a series of spins, as indicated by the manufacturer’s protocol. Cellular fractions were then quantified by Bradford assay (Thermo Scientific) and normalized based on total protein content to a 1-μg/μL final solution to be assessed via immunoblot.

Immunoblot Procedure and Analysis

HAECs were grown to confluence and then treated for the indicated period of time. Cells were lysed in whole-cell extraction buffer containing 62.5 mmol/L Tris-HCl (pH 6.8), 2% (wt/vol) sodium dodecyl sulfate, and 10% glycerol. Samples were then sonicated and diluted 1:5 in water, and protein content was measured using a BCA protein assay kit (Pierce). Total protein concentration was normalized to 3 μg/μL, and samples were then denatured in 1× LDS loading buffer (Life Technologies) with 1× reducing agent (Life Technologies) at 95°C for 5 minutes. Samples were then loaded at 10 μL per well into 4% to 12% Bis-Tris gels (Invitrogen) and separated out at 130 V for 2 hours. Protein was then transferred to polyvinylidene difluoride membranes (Immobilon) for 1.5 hour at 35 V. Following transfer, membranes were washed with TBST, and then blocked in 5% skim milk (Gibco) in TBST for 1 hour at room temperature. Membranes were then placed in primary antibodies (1:2000) on a shaker overnight at 4°C. The following day, membranes were washed 3× in TBST and then placed in secondary antibodies (1:2000) for 1 hour at room temperature. Blots were then washed 3× in TBST and placed in Amersham ECL detection solution (GE Health Sciences). Blots were imaged using the ChemiDoc MP system (Bio-Rad), and bands were quantified using ImageJ software (National Institutes of Health).

Antibodies

Rabbit polyclonal antibodies that recognize β-actin, phospho-(Ser536) and total NF-κB; phospho-(Thr-180/Tyr-182) and total p38 mitogen-activated protein kinase; and phospho-(Thr-202/Tyr-204) and total extracellular signal-related kinase 1/2 were purchased from Cell Signaling Technology. Horseradish peroxidase–conjugated secondary antibodies that recognize rabbit IgG were purchased from KLP Antibodies. Antibodies recognizing β-tubulin (rabbit) and lamin A/C were purchased from Santa Cruz Biotechnology.

Measurement of Plasma Metabolites

For plasma lipid-, lipoprotein-, and glucose-level determinations, mice were fasted for 4 hours before bleeding. Total cholesterol, high-density lipoprotein cholesterol, unesterified/free cholesterol, triglycerides, free fatty acid, and glucose levels were determined by enzymatic colorimetric assay. Quantification of TMAO and TMA in plasma samples was performed using stable isotope dilution high-performance liquid chromatography with online electrospray ionization tandem mass spectrometry on an AB SCIEX 5000 triple quadrupole mass spectrometer interfaced with a Shimadzu high-performance liquid chromatography system equipped with silica column (4.6 × 250 mm, 5 μm Luna Silica; Regis) at a flow rate of 0.8 mL/min, and the separation was performed, as reported previously.

Pharmacological Inhibitors

Inhibitors of NF-κB and G protein–coupled receptor (GPCR) signaling were treated as described in figure legends 5 and 6. NF-κB activation inhibitor IV (InSolution NF-κB inhibitor) and Gallein were purchased from Millipore. Pertussis toxin and BAY11-7082 were purchased from Sigma-Aldrich.

Leukocyte Adhesion Assay

This assay was adapted from previously published protocols. HAECs were stimulated for adhesion for 5 hours in RPMI media (Corning Scientific) containing 5% FBS (Atlanta Biologicals) with indicated treatments. At 2 hours prior to assay, leukocytes were spun down at 300 g for 10 minutes and pelleted. Cells were then resuspended in PBS containing 25 μmol/L Vybrant CFDA SE Cell Tracer (Life Technologies) for 15 minutes at 37°C. Labeled leukocytes were then spun down at 1000 rpm for 10 minutes and resuspended in RPMI media (Corning Scientific) with 5% FBS (Atlanta Biologicals). The spin and resuspension was repeated twice more to remove excess dye. Leukocytes were then added to HAECs for 30 minutes to allow adhesion. The combined cell mixture was then washed 3× with PBS to remove unbound leukocytes. Finally, cells were fixed in 4% paraformaldehyde and imaged. Quantification for adhesion assays were performed by placing a 1-mm grid over each image and counting the number of fluorescent points per 100-μm square. Each mean value reflects 9 images taken, 3 each from separate donors.

Mouse Macrophage Isolation

Primary mouse peritoneal macrophages were harvested, as described previously. Briefly, at 4 days prior to euthanasia, mice were intraperitoneally injected with 1 mL of 3.85% thioglycolate. Mice were then fasted overnight (~16 hours), and macrophages isolated by intraperitoneal lavage with sterile PBS. After overnight incubation, macrophages were
treated with various agents in DMEM supplemented with 5% FBS.

**Statistical Analysis**

Direct comparisons for experiments using a sample size >3 were performed using 2-tailed Student t tests. For some experiments in which n=3, nonparametric t tests using a Mann–Whitney test were performed. For these comparisons, sample median±25% of the median interquartile ranges were reported. For multiple comparisons testing, a 2-way ANOVA with a Tukey post hoc test was used. All statistical analyses were performed using R statistical software (R Foundation for Statistical Computing). Values were considered significant at \( P<0.05 \). All data are presented as mean±SE.

**Results**

**Chronic Choline Feeding Leads to Vascular Inflammation in Mice**

Given the importance of inflammation in atherosclerosis development, we initially tested whether chronic choline supplementation could promote inflammatory gene expression in cells of the vasculature. Atherosclerosis-prone LDLR\(^{-/-}\) \(-/-\) mice were fed a chemically defined diet, referred to as normal chow (0.07–0.08% total choline) or chow with 1.3% choline provided ad libitum in drinking water. After 3 weeks of diet, choline feeding did not alter serum lipid profiles or glucose levels (Figure 1A); however, a substantial increase in circulating TMAO was observed (Figure 1B). Aortas from these mice were probed using qPCR for expression of inflammatory genes. Choline-fed mice showed significantly enhanced expression of monocyte chemotactic protein 1, macrophage inflammatory protein 2, tumor necrosis factor-\( \alpha \), ICAM1, KC, cyclooxygenase 2, E-selectin, and VCAM1, as well as induction of the macrophage marker CD68 (Figure 1C).

**Acute TMAO Injection Activates Inflammatory Signaling and Gene Expression In Vivo**

We next tested whether the observed effects of long-term choline feeding could be recapitulated by acute TMAO administration. LDLR\(^{-/-}\) \(-/-\) mice were injected intraperitoneally with vehicle or a sterile solution of TMAO. The dose of TMAO used produced an initial spike in circulating levels to \( \approx100 \mu\text{mol/L} \) over the first hour, which returned essentially to near baseline levels \( \approx5 \) hours after injection in mice fed a normal chow diet (data not shown). Of note, the peak plasma TMAO levels with this protocol were similar to levels observed in mice chronically exposed to the choline-supplemented diet (Figure 1C) and in some human clinical studies.\(^9,10,17\) At

---

**Figure 1.** Choline feeding causes inflammation in atherosclerosis-prone mouse aortas that is accompanied by increased plasma choline, TMA, and TMAO but not lipids. A through C, LDLR\(^{-/-}\) female mice were fed chow or chow with either 0.07% (vehicle) or 1.3% choline for 3 weeks. Plasma was quantified for circulating levels of TG, TC, HDL, VLDL/IDL/LDL, UC, FFA, and glucose (A), as well as choline, TMA, and TMAO (B). Then aortas were harvested and quantitative polymerase chain reaction was used to quantify expression levels of inflammatory genes (C). All genes expressed as mean±SEM and normalized to RPL13A expression. \( n=8 \) mice per group; *\( P<0.05 \); **\( P<0.01 \). COX-2 indicates cyclooxygenase 2; E-Sel, E-selectin; FFA, free fatty acids; HDL, high-density lipoprotein; IDL, xxx; LDL, low-density lipoprotein; MCP-1, monocyte chemotactic protein 1; MIP-2, macrophage inflammatory protein 2; TC, total cholesterol; TG, triglyceride; TMA, trimethylamine; TMAO, trimethylamine N-oxide; TNF-a, tumor necrosis factor \( \alpha \); UC, unesterified cholesterol; VLDL, very low-density lipoprotein.
30 minutes after intraperitoneal injection of TMAO, aortas were harvested and then assessed for changes in activation of p38 mitogen-activated protein kinase, extracellular signal–related kinase 1/2, and p65 NF-κB, all of which have been shown to play substantial roles in cellular inflammation contributing to the development of atherosclerosis.18,20–24 Immediately following injection (30 minutes), TMAO-exposed mice showed elevated phosphorylation of functional residues on p38 mitogen-activated protein kinase (Thr-180/Tyr-182), extracellular signal–related kinase 1/2 (Thr-202/Tyr-204), and p65 NF-κB (Ser536) (Figure 2A and 2B). To show that the enhanced phosphorylation of p65 NF-κB was in fact leading to elevated nuclear abundance, the lysate was fractionated into nuclear and cytosolic regions. Consistent with the phosphorylation, TMAO increased nuclear abundance of total p65 NF-κB in these aortas (Figure 2C). The nuclear/cyttoplasmic ratios of p65 in aortas of vehicle- and TMAO-treated mice were 0.58 and 1.12, respectively. In addition, in a separate cohort of mice similarly injected with vehicle versus sterile TMAO, qPCR analysis of expression of inflammatory genes in aortas harvested 5 hours after injection showed significant elevations in cyclooxygenase 2, interleukin 6, E-selectin, and ICAM1 within the TMAO-administered group (Figure 2D). These data confirm that acute exposure to physiologically relevant levels of TMAO is sufficient to enhance inflammatory signaling and gene expression in aortas of atheroprone LDLR−/− mice.

TMAO Induces Inflammatory Signaling and Gene Expression in Human Endothelial and Smooth Muscle Cells

We next tested whether these in vivo observations could be recapitulated in primary cultures of HAEC and VSMC lines. We found that treatment of these 2 cell lines with TMAO resulted in phosphorylation of the p38 mitogen-activated protein kinase/extracellular signal–related kinase/NF-κB pathway (Figure 3A, 3B, 3E, and 3F), enhanced p65 NF-κB nuclear localization (Figure 3C and 3G), and induced inflammatory transcripts (cyclooxygenase 2, interleukin 6, E-selectin, and ICAM1) in HAECs (Figure 3D) and similar targets (cyclooxygenase 2, interleukin 6, tumor necrosis factor α, and ICAM1) in VSMCs (Figure 3H). Given the important role of macrophages in atherosclerosis, we also subjected primary mouse peritoneal macrophages to similar treatments and conditions. We did not observe overlapping functions for TMAO in inducing inflammatory gene expression after 6 hours of treatment, indicating a specific activity in HAECs and VSMCs compared with macrophages (Figure 3I). Nevertheless, we cannot rule out the possibility that a longer treatment period of TMAO may influence inflammatory gene expression in macrophages.

TMAO Efficacy for Enhancing Inflammation Surpasses That of TMA at Physiological Levels

Physiological ranges of TMAO are ≈10- to 20-fold higher than TMA in humans and ≈7.5-fold higher in various inbred strains of mice (data not shown). In LDLR−/− mice, we observed that TMAO levels were 14-fold higher than TMA in both chow and chow plus choline groups (Figure 1B). To assess the effective physiological ranges of TMA and TMAO, we tested the capacity of TMAO to exert its functions compared with equal concentrations of TMA, reflecting a supraphysiological concentration of TMA. Reaching statistical significance for only 3 observations (cyclooxygenase 2 expression in both cell types and E-selectin in HAECs), TMAO trended toward a more robust capacity to induce phosphorylation of NF-κB (Figure 4A, 4B, 4D and 4E) and enhance inflammatory gene expression (Figure 4C and 4F).

Activation of NF-κB and Gβγ Is Required for TMAO Effects on HAECs

To show that activation of signaling pathways is required for TMAO-induced inflammatory gene expression, a pharmacological inhibitor of NF-κB was used. A brief (30-minute) pretreatment with 100 nmol/L NF-κB activation inhibitor IV was sufficient to block TMAO-induced expression of target transcripts in both cell types (Figure 5A and 5B). The same experiments were confirmed using a different NF-κB inhibitor (BAY 11-7082), suggesting that inhibition of TMAO-induced target transcripts with either NF-κB activation inhibitor was not due to off-target pharmacological effects (data not shown). To investigate the presence of a specific receptor for TMAO using HAEC gene expression as a functional outcome, we performed similar experiments with broad-class inhibitors of GPCR subunit signaling in HAECs. Pharmacological inhibition of Gβγ by pretreatment with 10 μmol/L Gallein, but not 200 ng/mL Ga inhibitory pertussis toxin, abolished the capacity of TMAO to enhance downstream target transcripts in HAECs (Figure 5C through 5E). These observations suggest that activation of NF-κB and Gβγ signaling is required for TMAO to exert inflammatory effects on endothelial cells.

TMAO Enhances Endothelial Recruitment of Leukocytes

Increased leukocyte adhesion has been appreciated as a marker for endothelial cell activation, especially in the pathological context of atherosclerosis.23,24 To investigate whether TMAO can play a role in this perturbation, we adapted an assay to measure the capacity of endothelia to recruit activated leukocytes.18 Primary HAECs were briefly cultured in media in the presence versus absence of TMAO.
and then subsequently exposed to labeled leukocytes to monitor adhesion. TMAO pretreatment significantly enhanced leukocyte adherence compared with vehicle- or TMAO-treated HAECs (Figure 6A and 6B). To mechanistically link the inflammatory signaling activation via TMAO to this important functional outcome, the same experiment was performed using pretreatment with a pharmacological inhibitor of NF-κB signaling (NF-κB activation inhibitor IV). The NF-κB inhibitor effectively abolished the capacity of TMAO to enhance endothelial adhesion of leukocytes (Figure 6C and 6D). These
Figure 3. TMAO induces inflammation cascades and transcription in primary human endothelial and smooth muscle cells. A through C, Immunoblots (A), corresponding quantifications (B), and cell fractionations (C) of HAECs treated with vehicle (PBS) or TMAO (100 μmol/L) for 40 minutes (n=6). D, HAECs were treated with vehicle (PBS) or TMAO (200 μmol/L) for 6 hours and then quantified for inflammatory gene expression (n=6). E through H, The same experimental conditions were used as in panels A through D with primary VSMCs instead of HAECs. All data are expressed as mean±SEM. Immunoblot quantification was normalized to P-residue/total protein. β-actin and β-tubulin were used as the loading controls for HAECs and VSMCs, respectively, and quantitative polymerase chain reaction genes normalized to RPL13A expression. I, Mouse peritoneal macrophages were treated with indicated amounts of vehicle, trimethylamine, or TMAO (n=4 for each group) and then evaluated for inflammatory gene expression. All experiments were confirmed in at least 3 separate donors to confirm robust function. *P<0.05; **P<0.01; ***P<0.001. COX-2 indicates cyclooxygenase 2; E-Sel, E-selectin; ERK1/2 indicates extracellular signal–related kinase 1/2; HAEC, human aortic endothelial cell; IL-6, interleukin 6; MAPK, mitogen-activated protein kinase; NFkB, nuclear factor-κB; qPCR, quantitative polymerase chain reaction; TMAO, trimethylamine N-oxide; Veh, vehicle; VSMC, vascular smooth muscle cell.
observations link the inflammatory effects of TMAO to cardiovascular functional perturbations.

**Discussion**

Our observations support a role for TMAO in the activation of inflammatory pathways in cells of the vasculature, leading to endothelial cell leukocyte recruitment and atherosclerosis. Both in vivo studies in mice and in vitro studies in cultured HAECs and VSMCs revealed that physiological levels of TMAO could induce expression of cytokines and adhesion molecules. This activation was mediated, at least in part, by the NF-κB signaling pathway, which has been linked previously to reduced vascular responsiveness and inflammation.

An important question that remains is how this small molecule causes cellular activation of NF-κB signaling and subsequent events. Although a receptor for TMAO has not yet been identified, its physiological precursor TMA has been described as activating a GPCR, TAAR5. TAAR5 is thought to have evolved as a highly conserved olfactory receptor, enabling the detection of the pungent “fishy odor” of TMA. Genetic ablation of TAAR5 in mice removes an attraction to TMA odor. It has been shown that the TAAR5 receptor does not recognize TMAO, although given the structural similarity with TMA, a GPCR-mediated mechanism of TMAO action is a potential scenario. Our results suggest a likely GPCR-mediated mechanism for TMAO, specifically through activity of the Gβγ subunit complex in promoting endothelial cell inflammation.

TMAO also possesses several unique and intriguing biophysical properties. The molecule has been described to function as an organic osmolyte in shielding peptide regions from hydration, thus stabilizing structures and altering the protein folding process. Small amounts of TMAO have been predicted to cause condensed protein backbones (compared with other aqueous environments) in computa-
Furthermore, TMAO has been shown to function as a protein chaperone mimetic and to enable substantial protein stabilization. At high concentrations, it functions in freeze-avoidance responses, particularly in cold water–dwelling organisms that also commonly live in an environment under significant amounts of pressure. Some deep sea fish and crustaceans have taken advantage of these features; abundance of the molecule can be found in the muscle and other organs of many dwellers 1000 m below sea level. Consequently, the ability of TMAO to alter protein conformation may facilitate its mechanism of action, perhaps due to intercalation with cellular proteins, and consequent pathway activation. It is also notable that other small molecules such as ethanol have been described as affecting cell inflammation.

Figure 4. TMAO is more efficacious than TMA at affecting cell inflammation at physiological concentrations. A and B, HAECs were treated for 40 minutes with indicated concentrations of vehicle, TMA or TMAO, and then immunoblotted (A) and quantified (B) for phosphorylation of p65 NF-κB (Ser536) (n=3). C, HAECs were treated for 6 hours in the same conditions as were used in panels A and B and then subjected to qPCR for inflammatory gene expression (n=5). D-F, The same procedures were carried out as were used in panels A through C except with vascular smooth muscle cells instead of HAECs. All experiments were confirmed in at least 3 separate donors, and qPCR genes normalized to RPL13A expression. *P<0.05 vs vehicle treatment group; †P<0.05 of TMAO vs matched concentration of TMA. COX-2 indicates cyclooxygenase 2; E-Sel, E-selectin; HAEC, human aortic endothelial cell; IL-6, interleukin 6; NFκB, nuclear factor-κB; qPCR, quantitative polymerase chain reaction; TMA, trimethylamine; TMAO, trimethylamine N-oxide; TNF-a, tumor necrosis factor a; Veh, vehicle.
membrane and lipid raft fluidity, altering localization and function of signaling components such as NF-κB. It is easy to envision that the amphipathic character of the small TMAO molecule might similarly elicit such perturbations in membrane dynamics. Similarly, altering protein–protein or membrane–protein interactions could be an alternative mechanism for TMAO function.

Our studies by no means rule out other potential mechanisms by which TMAO may contribute to atherosclerosis. A previous report showed that TMAO enhanced uptake of cholesterol in peritoneal macrophages, a critical step in atherosclerosis. Although we did not observe TMAO inducing inflammation in macrophages, these observations could be due to differential regulation of receptor or signaling mechanisms across cell types. Varied responses to a biological compound mediated through tissue-specific receptor coupling has been observed for lysophosphatidic acid, which has been demonstrated to enhance p65 NF-κB phosphorylation in HAECs through GPCR-mediated activation of rho kinase, a phenomenon specific to endothelial cells. Additional studies

Figure 5. NFκB and Gβγ signaling is required for TMAO-induced inflammatory gene expression in endothelial and smooth muscle cells. A and B, HAECs (A) or vascular smooth muscle cells (B) were pretreated for 30 minutes with control (DMSO) or 100 nmol/L NFκB activation inhibitor followed by an overnight treatment with or without 200 μmol/L TMAO and probed by qPCR for inflammatory gene expression (n=6). ANOVA with a Tukey post hoc test was used with TMAO and inhibitor as the 2 factors. We did not observe interaction between inhibitor and TMAO groups. C through F, HAECs were pretreated for 1 hour with control (DMSO), 200 ng/mL PTX, or 10 μmol/L Gallein, followed by addition of vehicle (PBS) or 200 μmol/L TMAO, then probed by qPCR for inflammatory gene expression. All experiments were confirmed in at least 3 separate donors, and qPCR genes normalized to RPL13A expression. *P<0.05 compared with vehicle-alone group; †P<0.05 compared with TMAO-alone treatment group. COX-2 indicates cyclooxygenase 2; E-Sel, E-selectin; HAEC, human aortic endothelial cell; IL-6, interleukin 6; NFκB, nuclear factor-κB; PTX, pertussis toxin; qPCR, quantitative polymerase chain reaction; TMAO, trimethylamine N-oxide; TNF-α, tumor necrosis factor α; Veh, vehicle.
have shown that a single receptor underlies diverse cellular outcomes in response to lysophosphatidic acid treatment, such as neurite retraction, presumably through cell-type specific regulation of signaling intermediates (eg, rho). A similar scenario could exist in which TMAO treatment leads to different cellular outcomes through tissue-specific coupling of downstream events for a single GPCR.

Acknowledgments

We greatly thank Tiffany Wang for her help with RNA isolation and qPCR analysis and Rosa Chen for her help with manuscript preparation. We thank the laboratory of Dr Peter Tontonoz for the use of their microscopy facilities and the laboratory of Dr Luisa Iruela-Arispe for sharing their expertise on endothelial cell protocols.

Sources of Funding

This work was supported by NIH and Office of Dietary Supplements Grants T32HL69766 (Seldin), HL30568, NIH HL28481 and R01HL103866, P20HL113452, R01 HL103866 06A1, R01 DK106000, and NIH 2 P01 HL030568-31A1. Hazen is also supported by an endowment from the Leonard Krieger Fund. Mass spectrometry studies were performed in a facility supported in part by an AB SCIEX Center of Innovation Award.

Figure 6. TMAO enhances HAEC recruitment of activated leukocytes through NFκB. A, HAECs were stimulated for adhesive processes for 5 hours with vehicle (PBS) or 400 μmol/L TMA or TMAO then presented with prelabeled, activated leukocytes and quantified (C). B, The same procedure as was used in panel A was followed except a 1-hour inhibitor treatment (NFκB activation inhibitor) step was added prior to stimulation. D, Quantification of adhered leukocytes of panel B. ANOVA with a Tukey post hoc test was used with TMAO and inhibitor as the 2 factors. We did not observe interaction between inhibitor and TMAO groups. Images reflect representative examples of 9 images taken per group using 3 separate HAEC donor samples. Scale bars=100 μm. HAEC indicates human aortic endothelial cell; Inh, inhibitor; NFκB, nuclear factor-κB; TMA, trimethylamine; TMAO, trimethylamine N-oxide.

DOI: 10.1161/JAHA.115.002767

Journal of the American Heart Association

11
Disclosures
Hazen is named as the co-inventor on issued and pending patents held by the Cleveland Clinic relating to cardiovascular diagnostics and/or therapeutics; he is also paid as a consultant for the following companies: Esperion, and Procter & Gamble; and has received research funds from Astra Zeneca, Pfizer, Procter & Gamble, Roche Diagnostics Inc, and Takeda. Hazen reports having the right to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics and/or therapeutics from Cleveland Heart Laboratory, Siemens, Esperion, and Frantz Biomarkers, LLC.

References
Trimethylamine N–Oxide Promotes Vascular Inflammation Through Signaling of Mitogen–Activated Protein Kinase and Nuclear Factor–κB

Marcus M. Seldin, Yonghong Meng, Hongxiu Qi, WeiFei Zhu, Zeneng Wang, Stanley L. Hazen, Aldons J. Lusis and Diana M. Shih

*J Am Heart Assoc.* 2016;5:e002767; originally published February 22, 2016; doi: 10.1161/JAHA.115.002767

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://jaha.ahajournals.org/content/5/2/e002767

Subscriptions, Permissions, and Reprints: The *Journal of the American Heart Association* is an online only Open Access publication. Visit the Journal at http://jaha.ahajournals.org for more information.